Malignancy and Janus Kinase Inhibition

Rheumatic Disease Clinics of North America

Volumn 43, Issue 1, 2017, Pages 79-93

  Sivaraman, Padmapriya ^a,b,c   Cohen, Stanley B ^a,b,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b PRESBYTERIAN HOSPITAL OF DALLAS   (United States)

^c METROPLEX CLINICAL RESEARCH CENTER   (United States)

Author keywords

Jak inhibitors; Lung cancer; Lymphoma; Malignancy; Rheumatoid arthritis; Tofacitinib

Indexed keywords

BARICITINIB; BIOLOGICAL PRODUCT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; JANUS KINASE INHIBITOR; TOFACITINIB; UPADACITINIB; ANTIRHEUMATIC AGENT; JANUS KINASE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CAUSE OF DEATH; COLON CANCER; DRUG EXPOSURE; ENDOMETRIUM CANCER; HUMAN; KIDNEY CANCER; LEUKEMIA; LUNG CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; NON MELANOMA SKIN CANCER; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RHEUMATOID ARTHRITIS; SOLID TUMOR; STOMACH CANCER; THYROID CANCER; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; INCIDENCE; NEOPLASMS; SKIN NEOPLASMS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; INCIDENCE; JANUS KINASES; NEOPLASMS; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; SKIN NEOPLASMS;

EID: 85006256486     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2016.09.008     Document Type: Review

References (68)

1. 1 Hoes, J.N., Jacobs, J.W., Verstappen, S.M., et al. Adverse events of low to medium dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis 68 (2009), 1833–1838.
2. 2 Fortunet, C., Pers, Y.M., Lambert, J., et al. Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice. Rheumatology (Oxford) 54:4 (2015), 672–677.
3. 3 Seror, R., Dougados, M., Gossec, L., Glucocorticoid sparing effect of tumour necrosis factor alpha inhibitors in rheumatoid arthritis in real life practice. Clin Exp Rheumatol 27:5 (2009), 807–813.
4. 4 Navmann, L., Huscher, D., Detert, J., et al. Anti tumour necrosis factor alpha therapy in patients with rheumatoid arthritis results in a significant and long lasting decrease of concomitant glucocorticoid treatment. Ann Rheum Dis 68:12 (2009), 1934–1936.
5. 5 Mavers, M., Ruderman, E., Perlman, H., Intracellular signal pathways: potential for therapies. Curr Rheumatol Rep 11:5 (2009), 378–385.
6. 6 Genovese, M.C., Kremer, J., Zamani, O., et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 374:13 (2016), 1243–1252.
7. 7 Darnell, J.E., Kerr, I., Stark, G., Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264 (1994), 1415–1421.
8. 8 Pesu, M., Candotti, F., Husa, M., et al. Jak 3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. Immunol Rev 203 (2005), 127–142.
9. 9 Ghoreschi, K., Jesson, M., Li, X., et al. Modulation of innate and adaptive immune responses by tofacitinib. J Immunol 186:7 (2011), 4234–4243.
10. 10 Levine, R.L., Wadleigh, M., Cools, J., et al. Activating mutation in the tyrosine kinase Jak 2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7 (2005), 387–397.
11. 11 Harrison, C., Kiladjian, J., Al-Ali, H., et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New Eng J Med 366:9 (2012), 787–798.
12. 12 Tokumasa, N., Suto, A., Kagami, S., et al. Expression of Tyk 2 in dendritic cells is required for IL-12, IL-23, and IFN-gamma production and the induction of TH1 cell differentiation. Blood 110 (2007), 553–560.
13. 13 Kubler, K., Janus kinase inhibitors: mechanisms of action. Aust Prescr 37 (2014), 154–157.
14. 14 Hodge, J.A., Kawabata, T.T., Krishnaswami, S., et al. The mechanism of action of tofacitinib – an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 34:2 (2016), 318–328.
15. 15 Singh, J., Saag, K., Bridges, L., et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 68:1 (2016), 1–25.
16. 16 Smitten, A., Simon, T., Hochberg, M., A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther, 10, 2008, R45.
17. 17 Baecklund, E., Iliadou, A., Askling, J., Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54 (2006), 692–701.
18. 18 Bongartz, T., Sutton, A.J., Sweeting, M.J., Anti TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. Systemic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295 (2006), 2275–2285.
19. 19 Simon, T.A., Thompson, A., Gandhi, K.K., et al. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther, 17(1), 2015, 212.
20. 20 Chakravarthy, E.F., Genovesse, M.C., Association between rheumatoid arthritis and malignancy. Rheum Dis Clin North Am 30 (2004), 271–284.
21. 21 Wolfe, F., Michaud, K., Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 56 (2007), 2886–2889.
22. 22 National Cancer Institute. Surveillance, epidemiology and end results. Available at: http://seer.cancer.gov/.
23. 23 Wolfe, F., Michaud, K., Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti tumour necrosis factor therapy in 18,572 patients. Arthritis Rheum 50 (2004), 1740–1751.
24. 24 Olivo, L., Tayar, J.H., Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy. A meta-analysis. JAMA 308 (2012), 898–908.
25. 25 Codreanu, C., Damjanov, N., Safety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries. Biologics 9 (2015), 1–6.
26. 26 FDA Advisory Committee meeting briefing documents, FDA white Oak conference center, Maryland, May 9th, 2012.
27. 27 Curtis, J.R., Lee, E.B., Kaplan, I.V., et al. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme. Ann Rheum Dis 75:5 (2016), 831–841.
28. 28 Kremer, J.M., Bloom, B.J., Breedveld, F.C., et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 60 (2009), 1895–1905.
29. 29 Fleischmann, R., Cutolo, M., Genovese, M.C., et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease modifying antirheumatic drugs. Arthritis Rheum 64 (2012), 617–629.
30. 30 Tanaka, Y., Takeuchi, T., Yamanaka, H., et al. Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study. Mod Rheumatol 25:4 (2015), 514–521.
31. 31 Kremer, J.M., Cohen, S., Wilkinson, B.E., et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 64 (2012), 970–981.
32. 32 Burmester, G.R., Blanco, R., Charles-Schoeman, C., et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitors: a randomized phase 3 Trial. Lancet 381 (2013), 451–460.
33. 33 Lee, E.B., Fleischmann, R., Hall, S., et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 370 (2014), 2377–2386.
34. 34 Kremer, J., Li, Z.G., Hall, S., et al. Tofacitinib in combination with nonbiologic DMARDs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 159 (2013), 253–261.
35. 35 Fleischmann, R., Kremer, J., Cush, J., et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367 (2012), 495–507.
36. 36 Vollenhoven, V., Fleischmann, R., Cohen, S., et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 367 (2012), 508–519.
37. 37 Van der Heijde, D., Tanaka, Y., Fleischmann, R., et al. Tofacitinib in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from twenty four month phase III randomized radiographic study. Arthritis Rheum 65 (2013), 559–570.
38. 38 Wollenhaupt, J., Silverfield, J., Lee, E.B., et al. Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open label, long term extension studies. J Rheumatol 41 (2014), 837–852.
39. 39 Yamanaka, H., Tanaka, Y., Takeuchi, T., et al. Tofacitinib an oral Janus kinase inhibitor, as monotherapy or with background methotrexate in Japanese patients with rheumatoid arthritis: a phase 2/3 long-term extension study. Arthritis Rheum, 63, 2011, 1215 [abstract: S473].
40. 40 Mercer, L.K., Galloway, D.R., Dixon, L., et al. Risk of cancer in patients receiving non-biologic disease modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatology (Oxford) 52 (2013), 91–98.
41. 41 Askling, J., Fored, C.M., Brandt, L., et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumor necrosis factor antagonists. Ann Rheum Dis 64 (2005), 1421–1426.
42. 42 Kippers, R., Hodgkin's lymphoma. J Clin Invest 122 (2012), 3439–3447.
43. 43 Vose, J.M., Peripheral T cell non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 22:5 (2008), 997–1005.
44. 44 Sandin, S., Incidence of non-Hodgkin's lymphoma in Sweden, Denmark, and Finland from 1960 through 2003: an epidemic that was. Cancer Epidemiol biomarkers prev 15 (2006), 1295–1300.
45. 45 Chang, K.C., Huang, G.C., Jones, D., et al. Distribution and prognosis of WHO lymphoma subtypes in Taiwan reveals a low incidence of germinal-center derived tumors. Leuk Lymphoma 45 (2004), 1375–1384.
46. 46 Zintzaras, E., Risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 165 (2005), 2337–2344.
47. 47 Ekstrom, K., Hjalgrim, H., Brandt, L., et al. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum 48 (2003), 963–970.
48. 48 Baecklund, E., Askling, J., Rosenquist, R., et al. Rheumatoid arthritis and malignant lymphomas. Curr Opin Rheumatol 16 (2004), 254–261.
49. 49 Mariette, X., Cazals-Hatem, D., Warszawki, J., et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 99:11 (2002), 3909–3915.
50. 50 Bernatsky, S., Clarke, A.E., Suissa, S., Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med 168:4 (2008), 378–381.
51. 51 Askling, J., Baecklund, E., Granath, F., et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 68:5 (2009), 648–653.
52. 52 Taylor, A.L., Marcus, R., Bradley, A.J., Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol 56:1 (2005), 155–167.
53. 53 Caillard, S., Dharnidharka, V., Agodoa, L., et al. Post transplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 80:9 (2005), 1233–1243.
54. 54 Caillard, S., Lelong, C., Pessione, F., et al. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry. Am J Transplant 6:11 (2006), 2735–2742.
55. 55 Vincenti, F., Silva, T.H., Busque, S.O., et al. Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. Am J Transplant 12 (2012), 2446–2456.
56. 56 Curtis JR, Lee EB, Martin G, et al. Analysis of non-melanoma skin cancer across the tofacitinib rheumatoid arthritis clinical program, 16th annual European congress of rheumatology, Rome (Italy), June 10-13, 2015.
57. 57 Gridley, G., Mclaughlin, J.K., Ekbom, A., et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 85 (1993), 307–311.
58. 58 Mellemkjaer, L., Linet, M.S., Gridley, G., et al. Rheumatoid arthritis and cancer risk. Eur J Cancer 32A (1996), 1753–1757.
59. 59 Chakravarty, E.F., Michaud, K., Wolfe, F., Skin cancer, rheumatoid arthritis and tumor necrosis factor inhibitors. J Rheumatol 32 (2005), 2130–2135.
60. 60 Dreyer, L., Mellemkjaer, L., Anderson, A.R., et al. Incidence of overall and site specific cancers in TNF alpha inhibitor treated patients with rheumatoid arthritis and other arthritides–a follow up study from the DANBIO Registry. Ann Rheum Dis 72 (2013), 79–82.
61. 61 Moulis, G., Sommet, A., Bene, J., et al. Cancer risk and Anti TNF alpha at recommended doses in adult rheumatoid arthritis: a meta analysis with intention to treat and per protocol analyses. PLoS One, 7, 2012, e48991.
62. 62 Raaschou, P., Rheumatoid arthritis, anti-tumour necrosis factor treatment and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden. BMJ, 352, 2016, i262.
63. 63 Askling, J., Fahrbach, K., Nordstrom, B., et al. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 20 (2011), 119–130.
64. 64 Abasolo, L., Judez, E., Descalzo, M., et al. Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a south European population. Semin Arthritis Rheum 37 (2008), 388–397.
65. 65 Setoguchi, S., Solomon, D.H., Weinblatt, M.E., et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 54 (2006), 2757–2764.
66. 66 Keystone, E., Emery, P., Camp, H., et al. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis 74 (2015), 333–340.
67. 67 Tanaka, Y., Emoto, K., Cai, Z., et al. Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: a 12 week, double blind, randomized placebo controlled study. J Rheumatol 43:3 (2016), 504–511.
68. 68 Kremer JM, Keystone EC, Emery P, et al. Selective Jak 1 inhibitor in patients with active rheumatoid arthritis and inadequate response or intolerance to anti-TNF biologic therapy. 2015 ACR/ARHP Annual Meeting. [abstract: 14L].